Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takeda
Biotech
Merck mulls PV program’s future while Takeda takes victory lap
Merck revealed the first look at data from a phase 2 trial of bomedemstat, while Takeda shared updated results from rusfertide's phase 3 study.
Darren Incorvaia
Dec 8, 2025 4:30pm
Neurocrine-Takeda psychiatry pact suffers another phase 2 fail
Nov 11, 2025 6:25am
Takeda drops AZ-partnered neurological program after ph. 2 fail
Oct 30, 2025 9:25am
Takeda strikes Innovent pact worth up to $11.4B
Oct 22, 2025 9:15am
BioCryst inks $700M Astria deal to rival Takeda in rare disease
Oct 14, 2025 10:30am
Takeda turns to AI drug designer after whittling down R&D focus
Oct 14, 2025 5:00am
